Australian scientists report that obese patients who were placed on a low-calorie diet and took ezetimibe had reduced inflammation, hepatic steatosis and cardiovascular risk factors. A study of 25 obese patients found those who received ezetimibe showed lower levels of triglycerides, LDL cholesterol and other markers after four months compared with those who dieted only.

Related Summaries